ESR1 and breast carcinoma: Suffice to say the translational laboratory research work in the 1970’s [15] that catalyzed tamoxifen’s move from orphan drug resulted in tamoxifen becoming the standard of care for the long term adjuvant therapy of estrogen receptor (ER) positive breast cancer and, as a result, extended the lives of millions of women worldwide.